Press releases

  2019/12/19 6:00PM
|

Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension

→ pdf
  2019/12/16 6:00PM
|

Quantum Genomics to Participate in Biotech Showcase 2020

→ pdf
  2019/12/09 6:00PM
|

Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America

→ pdf
  2019/10/07 07:30AM
|

Quantum Genomics enters into exclusive negotiations for its first partnership

→ pdf
  2019/10/03 6:00PM
|

Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

→ pdf
  2019/09/11 7:35PM
|

Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure

→ pdf
  2019/09/02 6:00PM
|

Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension

→ pdf
  2019/07/03 6:00PM
|

Quantum Genomics Selected to Enter the European Rising Tech Label

→ pdf
  2019/06/27 6:00PM
|

Quantum Genomics Announces Result of Annual General Meeting

→ pdf
  2019/06/12 6:00PM
|

A key milestone reached by Quantum Genomics in the development of firibastat

→ pdf
  2019/06/06 6:00PM
|

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients

→ pdf
  2019/05/10 12:00AM
|

Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension

→ pdf
  2019/04/26 2:00PM
|

Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation

→ pdf
  2019/04/17 6:00PM
|

Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure

→ pdf
  2019/03/28 6:00PM
|

Quantum Genomics Reports Full-Year 2018 Financial Results

→ pdf
  2019/03/20 6:00PM
|

Quantum Genomics Announces Positive Results from New Preclinical Studies on Firibastat

→ pdf
  2019/02/25 6:00PM
|

Quantum Genomics Completes Enrollment in Its Pharmacokinetic Clinical Study of Firibastat

→ pdf
  2019/02/06 6:00PM
|

Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure

→ pdf
  2019/01/31 6:45PM
|

Quantum Genomics Presents its 2019 Corporate Action Plan

→ pdf
  2019/01/23 6:00PM
|

The Association of Black Cardiologists and the Heart Institute of the Caribbean Conclude Successful First Annual Joint "Masters of Cardiology" Conference in Kingston, Jamaica

→ pdf
  2019/01/17 6:00PM
|

Quantum Genomics Appoints Steering Committee for its Phase III Pivotal Trial in Resistant Hypertension

→ pdf

Each PDF has been scanned by antimalware and incorporates a SECURITY MASTER Footprint. To check its authenticity:
www.security-master-footprint.com

Party powered automatically by Actusnews Wire ©
(Primary Information Provider)